Open-Label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse.

Trial Profile

Open-Label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Iodine I 131 derlotuximab biotin (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Oct 2011 Status changed from active, no longer recruiting to completed, according to a SIRO Clinpharm media release.
    • 07 Jun 2011 Interim results were presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
    • 19 May 2011 Interim results have been reported in a Peregrine Pharmaceuticals media release; additional results will be reported at ASCO-2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top